1601 related articles for article (PubMed ID: 21358461)
1. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up.
Lorenzo D; Arias L; Alcubierre R; Pujol O; Caminal JM; Rubio M; Català J; Garcia-Bru P; Arruga J
Ophthalmologica; 2011; 226(3):103-9. PubMed ID: 21720153
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
5. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
6. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
7. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.
Arias L; Roman I; Masuet-Aumatell C; Rubio MJ; Caminal JM; Catala J; Pujol O
Retina; 2011; 31(7):1261-7. PubMed ID: 21499194
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
9. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up.
El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N
Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.
Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F
Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164
[TBL] [Abstract][Full Text] [Related]
15. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
Sabry D; Gad MA; Enam KM
Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with intravitreal injection of ranibizumab and reduced fluence photodynamic therapy for choroidal neovascularization secondary to angioid streaks: preliminary clinical results of 12-month follow-up.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Senel A; Bahcecioglu H
Retina; 2011; 31(7):1279-86. PubMed ID: 21394063
[TBL] [Abstract][Full Text] [Related]
17. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
Varano M; Tedeschi M; Oddone F; Perillo L; Coppè AM; Parravano M
Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks.
Mimoun G; Tilleul J; Leys A; Coscas G; Soubrane G; Souied EH
Am J Ophthalmol; 2010 Nov; 150(5):692-700.e1. PubMed ID: 20719301
[TBL] [Abstract][Full Text] [Related]
20. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Arevalo JF; Fardeau C; Hrisomalos EN; Chan WM; Lai TY; Ziemssen F; Ness T; Sibai AM; Mackensen F; Wolf A; Hrisomalos N; Heiligenhaus A; Spital G; Jo Y; Gomi F; Ikuno Y; Akesbi J; LeHoang P; Adan A; Mahendradas P; Khairallah M; Guthoff R; Ghandour B; Küçükerdönmez C; Kurup SK
Can J Ophthalmol; 2012 Jun; 47(3):269-74. PubMed ID: 22687305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
